PFC
PGNX

Phocas Financial Corp’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Phocas Financial Corp’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,022,708
Closed -$5.17M – 206
2019
Q3 		$5.17M Sell
1,022,708
-10,620
-1% -$53K 0.55% 77
2019
Q2 		$6.38M Sell
1,033,328
-112,964
-10% -$545K 0.68% 66
2019
Q1 		$5.32M Sell
1,146,292
-551,957
-33% -$2.5M 0.53% 84
2018
Q4 		$7.13M Sell
1,698,249
-38,137
-2% -$194K 0.8% 54
2018
Q3 		$10.9M Sell
1,736,386
-26,592
-2% -$204K 0.95% 38
2018
Q2 		$14.2M Sell
1,762,978
-16,546
-0.9% -$126K 1.22% 15
2018
Q1 		$13.3M Buy
1,779,524
+340,217
+24% +$2.26M 1.2% 20
2017
Q4 		$8.56M Sell
1,439,307
-60,978
-4% -$370K 0.72% 64
2017
Q3 		$11K Buy
1,500,285
+33,537
+2% +$213K 0.92% 47
2017
Q2 		$9.96M Buy
1,466,748
+65,491
+5% +$483K 0.9% 47
2017
Q1 		$13.2M Sell
1,401,257
-190,205
-12% -$1.9M 1.23% 16
2016
Q4 		$13.8M Sell
1,591,462
-1,626
-0.1% -$12K 0.91% 24
2016
Q3 		$10.1M Buy
1,593,088
+943,793
+145% +$5.71M 0.7% 45
2016
Q2 		$2.74M Buy
649,295
+39,332
+6% +$190K 0.2% 180
2016
Q1 		$2.66M Sell
609,963
-25,370
-4% -$113K 0.2% 179
2015
Q4 		$3.9M Buy
635,333
+45,414
+8% +$298K 0.31% 156
2015
Q3 		$3.37M Buy
589,919
+40,632
+7% +$312K 0.29% 161
2015
Q2 		$4.1M Sell
549,287
-706,358
-56% -$4.27M 0.33% 148
2015
Q1 		$7.51M Buy
1,255,645
+208,464
+20% +$1.31M 0.6% 70
2014
Q4 		$7.92M Sell
1,047,181
-42,564
-4% -$255K 0.69% 43
2014
Q3 		$5.66M Buy
1,089,745
+157,865
+17% +$787K 0.51% 90
2014
Q2 		$4.02M Buy
931,880
+126,285
+16% +$482K 0.35% 130
2014
Q1 		$3.29M Buy
805,595
+180,522
+29% +$923K 0.32% 134
2013
Q4 		$3.33M Buy
+625,073
New +$2.75M 0.31% 144

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Phocas Financial Corp's PGNX Position: Q4 2019 in Review

Phocas Financial Corp sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2019, closing a stake of 1,022,708 shares — an estimated $5.17M sold.

Phocas Financial Corp first reported a position in PGNX in Q4 2013 and held it in 24 quarters. The position peaked at $14.2M in Q2 2018. 128 funds tracked by Wall St. Rank hold PGNX as of Q4 2019.

  • Phocas Financial Corp reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2019 after selling out during the quarter.
  • Phocas Financial Corp sold 1,022,708 Progenics Pharmaceuticals Inc shares in Q4 2019, an estimated $5.17M.
  • Phocas Financial Corp first reported a position in Progenics Pharmaceuticals Inc in Q4 2013 and held it in 24 quarters.
  • Phocas Financial Corp's Progenics Pharmaceuticals Inc position peaked at $14.2M in Q2 2018.
  • 128 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2019.

Based on Phocas Financial Corp's 13F filing for Q4 2019, filed 14 Feb 2020.